NanoPhoria
NA
NA
NanoPhoria
Developing inhalable therapies for cardiovascular diseases using a proprietary nanoparticle platform.
About
NanoPhoria is a preclinical-stage biotechnology company focused on developing novel inhalable therapies for cardiovascular diseases. Their core technology utilizes a proprietary, non-viral calcium phosphate nanoparticle platform designed to deliver biologics, such as peptides and RNA, directly to target tissues. This approach aims to enhance treatment effectiveness and minimize systemic side effects by enabling precise, tissue-directed drug delivery via inhalation, with an initial focus on conditions like heart failure.
Competitors & alternatives (6)
NanoPhoria alternatives 
Key facts
At-a-glance profile data
- Headquarters
- Italy
- Total funding
- $84M (null)
- Business model
- B2B
Add first review
Frequently asked
How much funding has NanoPhoria raised?
NanoPhoria has raised a total of $84M in funding. The most recent round on record is null.